Edina Cenko Shared STRIVE Trial – Intracoronary Alteplase Shows No Advantage in STEMI
Edina Cenko, Chairperson of ESC Working Group on Coronary Pathophysiology and Microcirculation, posted on LinkedIn:
”The STRIVE trial showed that intracoronary alteplase during primary PCI for STEMI with high thrombus burden did not improve MACE, ST-segment resolution or myocardial blush grade compared with placebo, with a signal toward more ventricular fibrillation.
Once more, no adjunctive strategy has yet succeeded in improving downstream microvascular perfusion after epicardial flow is restored. The search for an effective solution in MVO after STEMI continues.”
Read the study here.
Title: Intracoronary Low-Dose Recombinant Tissue Plasminogen Activator in Primary PCI for ST-Segment Elevation Myocardial Infarction and Large Thrombus Burden: A Randomized Trial
Authors: Shamir R. Mehta, Natalia Pinilla-Echeverri, Denise Tiong, Tanya Kovalova, Tej Sheth, Madhu K. Natarajan, Matthew Sibbald, James L. Velianou, Robert Welsh, Bryan Har, Sanjit S. Jolly, Nicholas Valettas, J.D. Schwalm, Michael Tsang, Rutaba Khatun, Rajibul Mian, Jennifer Cunningham, Eric Ly, Tara McCready, Kevin R. Bainey
Stay updated with Hemostasis Today.
-
Jan 9, 2026, 09:25Emma Groarke Shares A Comprehensive Review on VEXAS Syndrome
-
Jan 9, 2026, 09:13Anirban Sen Gupta Presents PlateChek
-
Jan 9, 2026, 08:58Oscar Pena Shares KDIGO 2026 Update: 5 Critical Changes for Anemia in CKD Management
-
Jan 9, 2026, 07:38Bartosz Hudzik on Subacute Coronary Occlusions: Navigating the Gray Zone in CAD Care
-
Jan 9, 2026, 07:27Gregory Piazza on The Role of D-Dimer in VTE Evaluation
-
Jan 9, 2026, 07:19Emmanuel J Favaloro Shares the 1st Article in a VWD Series Marking the 100-Year Anniversary
-
Jan 9, 2026, 07:07Taylor Robichaux on Recombinant ADAMTS13 Therapy in cTTP
-
Jan 9, 2026, 06:25Sara Ng: VTE Continues to Plague Modern Oncology
-
Jan 9, 2026, 06:12James Caldwell on The Hidden Culprit in Perimesencephalic SAH